Abstract | BACKGROUND: In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen-signalling-targeted inhibitor. However, some patients received docetaxel or the prior alternative androgen-signalling-targeted inhibitor in the metastatic hormone-sensitive (mHSPC) setting. Therefore, the CARD results cannot be directly translated to a Japanese population. METHODS: RESULTS: A total of 222 patients (median age 70 years) were included in this subanalysis. Median number of cycles was higher for cabazitaxel versus androgen-signalling-targeted inhibitors (7 versus 4). Clinical outcomes favoured cabazitaxel over abiraterone or enzalutamide including, radiographic progression-free survival (rPFS; median 8.2 versus 3.4 months; P < 0.0001), overall survival (OS; 13.9 versus 11.8 months; P = 0.0102), PFS (4.4 versus 2.7 months; P < 0.0001), confirmed prostate-specific antigen response (37.0 versus 14.4%; P = 0.0006) and objective tumour response (38.9 versus 11.4%; P = 0.0036). For cabazitaxel versus androgen-signalling-targeted inhibitor, grade ≥ 3 adverse events occurred in 55% versus 44% of patients, with adverse events leading to death on study in 2.7% versus 5.7%. CONCLUSIONS:
|
Authors | Hiroyoshi Suzuki, Daniel Castellano, Johann de Bono, Cora N Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Meredith C Foster, Ayse Ozatilgan, Christine Geffriaud-Ricouard, Ronald de Wit |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 51
Issue 8
Pg. 1287-1297
(Aug 01 2021)
ISSN: 1465-3621 [Electronic] England |
PMID | 33738495
(Publication Type: Journal Article)
|
Copyright | © The Author(s) 2021. Published by Oxford University Press. |
Chemical References |
- Androstenes
- Benzamides
- Nitriles
- Taxoids
- Phenylthiohydantoin
- cabazitaxel
- enzalutamide
- Prostate-Specific Antigen
- abiraterone
|
Topics |
- Aged
- Androstenes
- Benzamides
- Disease-Free Survival
- Humans
- Male
- Nitriles
- Phenylthiohydantoin
- Prostate-Specific Antigen
- Prostatic Neoplasms, Castration-Resistant
(drug therapy)
- Taxoids
- Treatment Outcome
|